1ST.AX 1st Group (ASX) +22.22% intraday on 11 Feb 2026: volume spike hints momentum

1ST.AX stock jumped 22.22% intraday to A$0.011 on 11 Feb 2026 on unusually heavy trade. Volume reached 2,075,140 shares versus an average of 678,621, a relative volume of 3.06 that pushed the price above the 50-day average of A$0.00917. The move is driven by short-term buying pressure in the ASX healthcare small-cap group and increased retail interest. Traders should note the company’s small market cap of A$15,586,889 and negative earnings per share of -A$0.01, which keep this a high-risk, high-volatility intraday play.

Intraday price action for 1ST.AX stock

Shares of 1st Group Limited (1ST.AX) rose 22.22% from a prior close of A$0.009 to A$0.011 on 11 Feb 2026, with the session range locked at A$0.011. The spike coincided with a volume surge to 2,075,140 shares, roughly three times average, signaling momentum traders pushed the move.

Financials and valuation for 1ST.AX stock

1st Group reports EPS -A$0.01 and a negative PE at -1.10, reflecting losses. Market capitalisation stands at A$15,586,889 with 1,416,989,952 shares outstanding. Key ratios include price to sales 3.49 and current ratio 0.83, which highlight thin liquidity and a stretched working-capital position.

Meyka AI grade and technical view on 1ST.AX stock

Meyka AI rates 1ST.AX with a score out of 100: 65.39 / 100 — Grade B — SUGGESTION: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst signals. Technicals show price above the 50-day average (A$0.00917) but near the 200-day (A$0.00796), so momentum is short-lived without follow-through.

Forecasts and price targets for 1ST.AX stock

Meyka AI’s forecast model projects a yearly price of A$0.007 versus the intraday price A$0.011, implying an expected downside of -36.36% from today’s level. Short-term realistic targets: bull case A$0.015 (36.36% upside), base case A$0.012 (9.09% upside) and downside support A$0.005 (-54.55%). Forecasts are model-based projections and not guarantees.

Risks and opportunities for 1ST.AX stock

Opportunities: recovery in healthcare marketplace revenue, SaaS adoption for GoBookings and telehealth integrations could lift multiples. Risks: negative operating margins, cash burn (operating cashflow per share -0.00278), stretched payables and low liquidity make the stock vulnerable to dilution and sharp downswings.

Sector context and trading notes for 1ST.AX stock

1ST.AX trades in the ASX Healthcare information services subsector where large-cap peers show stronger margins and balance sheets. Healthcare sector performance YTD is positive but uneven; small-cap healthcare names can gap higher intraday. For trade execution, use limit orders and size positions to account for low float and high volatility. See market coverage and live quotes on our Meyka stock page: 1ST.AX on Meyka.

Final Thoughts

Intraday momentum pushed 1ST.AX stock to A$0.011 on 11 Feb 2026, driven by a 22.22% rise and a volume surge to 2,075,140 shares. That activity signals short-term buyer interest but fundamentals remain weak: EPS -A$0.01, negative PE and constrained liquidity. Meyka AI’s model projects A$0.007 over a 12-month horizon, implying a -36.36% downside from today’s price; that highlights model caution. Near-term price action could revisit the year high A$0.015 if revenue or partnership updates arrive, but downside risk to A$0.005 is credible without improved cash flow. We view 1ST.AX as a speculative small-cap trade for intraday momentum and reaction-driven strategies, not a stable core holding. Use tight risk controls, size positions conservatively, and follow official company updates and market news when trading on the ASX. This article includes Meyka AI-powered market analysis and is informational only, not investment advice. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.